This article is more than 5 years old. Information may no longer be current.

IRIS Registry advances science of ophthalmology

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LAS VEGAS — The American Academy’s IRIS Registry is an industry game changer and advances the science of ophthalmology, according to a speaker here.

The Intelligence Research in Sight (IRIS) Registry is the nation’s first eye disease clinical database.

David W. Parke II

The IRIS Registry “is a system wherein data from a number of the EHRs is uploaded into a cloud-based system and injected into analytics to be used as a way for ophthalmologists to view their own care and benchmark themselves with a number of different peer groups,” David W. Parke II, MD, CEO of the American Academy of Ophthalmology, said at the Ophthalmology Innovation Summit.

“This really is the way of the future,” Parke said, adding that the dataset that is now “the largest comprehensive specialty registry in the world.”

The registry integrates with 39 electronic health records (EHRs), which can effectively reach the entire ophthalmic community in the U.S., he said.

Since the launch of the registry 18 months ago, approximately 80% of all ophthalmologists in the U.S. who are able to participate in the registry are participating. The registry accounts for more than 60 million unique patient visits and 18 million unique patients.

Parke anticipates that 140 million unique patient visits will be registered by the end of 2016.

“What really makes it advantageous is that this is real-world data. This is not something that is coming out of someone’s phase 2 or phase 3 trial using the standardized protocol. This represents how care is being delivered by ophthalmologists both in academia and private practice around the country,” Parke said.

The dataset in ophthalmology is bigger than the entire Medicare dataset and is estimated to represent 49% of the U.S. visit volume total, he said.

“I think this — and I’m very biased — is a real game changer for all of us in the world of innovation and ophthalmology,” Parke said. — by Nhu Te

Reference:

Parke D. Ophthalmic Innovation 2015: A View from AAO. Presented at: Ophthalmology Innovation Summit. Nov. 12, 2015; Las Vegas.

Disclosure: Parke reports that he is the CEO of the American Academy of Ophthalmology.